Eledon Pharmaceuticals In... (ELDN)
4.13
-0.02 (-0.48%)
At close: Mar 03, 2025, 11:57 AM
Eledon Pharmaceuticals Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Revenue | n/a | n/a | n/a | 120K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 374K | 373K | 195K | 183K | 182K | 11K | 22K | 35K | 109K | 58.00 | n/a | n/a |
| Gross Profit | -374K | -373K | -195K | -63K | -182K | -11K | -22K | -35K | -109K | -58 | n/a | n/a |
| Operating Income | -43M | 8.49M | -36.87M | -18.46M | -16.05M | -14.06M | -13.12M | -38.12M | -45.26M | -23.46M | -15.75M | -9.65M |
| Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pretax Income | -40.33M | -87.97M | -36.86M | -23.21M | -16.01M | -14.06M | -13.12M | -37.96M | -45.09M | -23.3M | -15.72M | -9.65M |
| Net Income | -40.33M | -87.5M | -34.51M | -22.81M | -17.88M | -14.06M | -13.12M | -37.96M | -45.09M | -23.3M | -15.72M | -9.65M |
| Selling & General & Admin | 12.69M | 12.7M | 13.13M | 10.05M | 6.06M | 7.24M | 11.1M | 13.1M | 12.62M | 8.88M | 3.55M | 2.28M |
| Research & Development | 30.31M | 27.08M | 23.73M | 6.13M | 8.13M | 6.82M | 2.02M | 25.02M | 32.64M | 14.58M | 12.2M | 7.37M |
| Other Expenses | n/a | 462K | 7K | 79K | 40K | -5K | 5K | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 43M | 39.78M | 36.87M | 16.18M | 14.18M | 14.06M | 13.12M | 38.12M | 45.26M | 23.46M | 15.75M | 9.65M |
| Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 174K | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 43M | 39.78M | 36.87M | 16.18M | 14.18M | 14.06M | 13.12M | 38.12M | 45.26M | 23.46M | 15.75M | 9.65M |
| Income Tax | n/a | -462K | -2.35M | -404K | 1.87M | -5K | n/a | 136K | n/a | -187K | n/a | n/a |
| Shares Outstanding (Basic) | 24.62B | 14.29M | 14.82M | 1.45M | 655.52K | 500.3K | 259.87K | 21.26K | 138.79K | 39.93K | 94.8K | 94.8K |
| Shares Outstanding (Diluted) | 24.62M | 14.29M | 14.82M | 1.45M | 655.52K | 500.3K | 259.87K | 21.26K | 138.79K | 39.93K | 94.8K | 94.8K |
| EPS (Basic) | -0.00 | -6.13 | -2.33 | -15.72 | -27.27 | -28.11 | -50.47 | -1.79K | -324.85 | -583.36 | -165.87 | -101.78 |
| EPS (Diluted) | -1.64 | -6.13 | -2.33 | -15.72 | -27.27 | -28.11 | -50.47 | -1.79K | -324.85 | -583.36 | -165.87 | -101.78 |
| EBITDA | n/a | -87.59M | -36.66M | -23.03M | -15.83M | -14.05M | -13.1M | -6.9M | -44.98M | -23.27M | -15.71M | -9.64M |
| Depreciation & Amortization | 43M | 373K | 195K | 183K | 182K | 11K | 22K | 35K | 109K | 21K | 10K | 9K |